M1RN34.SA Moderna Inc
- Market cap
- BRL 568B
- P/E
- -
- P/B
- 13.68x
- ROE
- -62.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is M1RN34.SA undervalued?
Graham numberThe Graham number of Moderna Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Moderna Inc fundamental analysis
No fundamental analysis for Moderna Inc yet.
Moderna Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Moderna Inc
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines;…
Full company profileModerna Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Moderna Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 108M | 206M | 135M | 60.2M | 803M | 18.5B | 19.3B | 6.85B | 3.24B | 1.94B | 1.06B |
| Gross Profit | - | - | - | - | 795M | 15.9B | 13.8B | 4.36B | 2.27B | 1.37B | -1.03B |
| Operating Income | -224M | -269M | -413M | -546M | -763M | 13.3B | 9.42B | -4.24B | -3.95B | -3.07B | -4.41B |
| EBITDA | - | -249M | -388M | -477M | -703M | 13.5B | 9.95B | -3.62B | -3.39B | -2.54B | -3.89B |
| Net Income | -216M | -256M | -385M | -514M | -747M | 12.2B | 8.36B | -4.71B | -3.56B | -2.82B | -4.25B |
| EPS | - | -0.79 | -1.17 | -1.53 | -1.87 | 30 | 22 | -12 | -9.23 | -7.16 | -11 |
| Balance Sheet | |||||||||||
| Total Assets | 1.42B | 1.08B | 1.96B | 1.59B | 7.34B | 24.7B | 25.9B | 18.4B | 14.1B | 12.3B | 11.0B |
| Total Liabilities | 575M | 459M | 432M | 415M | 4.78B | 10.5B | 6.74B | 4.57B | 3.24B | 3.69B | 4.20B |
| Shareholders' Equity | 842M | 625M | 1.53B | 1.17B | 2.56B | 14.1B | 19.1B | 13.9B | 10.9B | 8.65B | 6.76B |
| Cash & Short-term Investments | 1.06B | 756M | 1.52B | 1.10B | 4.61B | 10.7B | 9.90B | 8.60B | 7.03B | 5.80B | 1.72B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 66.7M | -331M | -331M | -459M | 2.03B | 13.6B | 4.98B | -2.08B | -3.00B | -1.87B | -2.31B |
| Capital Expenditure | 33.1M | 58.4M | 106M | 32.0M | 68.0M | 284M | 400M | 579M | 1.05B | 202M | 198M |
| Free Cash Flow | - | -390M | -437M | -491M | 1.96B | 13.3B | 4.58B | -2.66B | -4.06B | -2.08B | -2.51B |
| Ratios | |||||||||||
| ROE | -25.7% | -40.9% | -25.1% | -43.8% | -29.2% | 86.3% | 43.7% | -34.0% | -32.7% | -32.6% | -62.9% |
| ROA | -15.3% | -23.6% | -19.6% | -32.3% | -10.2% | 49.5% | 32.3% | -25.6% | -25.2% | -22.9% | -38.8% |
| Net Profit Margin | -199.5% | -124.3% | -284.8% | -853.7% | -93.0% | 66.1% | 43.4% | -68.8% | -110.0% | -145.2% | -399.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Moderna Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | BRL 1.48M | 0.00 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Nov 21, 2022.
Who owns Moderna Inc
- Insiders 0.00%
- Institutions 0.00%
- Public & others 100.00%
- Shares outstanding 7.98B
- Free float 3.72B
Moderna Inc company profile
- Company name
- Moderna Inc
- Ticker
- M1RN34.SA
- Exchange
- Sao Paulo Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4,700
- Fiscal year end
- December
- Address
- 325 Binney Street, Cambridge, MA, United States, 02142
- Phone
- 617 714 6500
- Website
- modernatx.com
About Moderna Inc
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Moderna Inc management
10- Mr. Stéphane Bancel M.B.A.CEO & Director · born 1973
- Dr. Stephen Hoge M.D.President · born 1976
- Mr. James M. MockChief Financial Officer · born 1977
- Ms. Shannon Thyme Klinger J.D.Chief Legal Officer & Corporate Secretary · born 1971
- Mr. Juan AndresChief Operating Officer · born 1965
- Ms. Lavina Talukdar CFASenior VP & Head of Investor Relations · born 1974
- Chris RidleyVP & Global Head of Communications
- Ms. Tracey FranklinChief People & Digital Technology Officer · born 1980
- Dr. Charbel Haber M.P.H., Ph.D.Senior VP & Head of Global Regulatory Science
- Mr. Patrick Norman BergstedtSenior Vice President of Commercial Vaccines · born 1962